Table 2 Odds ratios and 95% confidence intervals for associations between individual metabolites (per 1SD increase in metabolite level) and breast cancer incidence, with metabolites reaching nominal significance, in the Nurses’ Health Study II (1996–2011).

From: Prospective study of circulating metabolomic profiles and breast cancer incidence among predominantly premenopausal women

Metabolite

HMDB ID

Class

Model 1 OR (95% CI)

Model 1 P-value

Model 2 OR (95% CI)

Model 2 P-value

Model 3 OR (95% CI)

Model 3 P-value

Taurodeoxycholate

HMDB0000896

Bile acids, alcohols and derivatives

1.15 (1.05–1.26)

0.004

1.15 (1.05–1.27)

0.004

1.15 (1.04–1.28)

0.009

C16:1 CE

HMDB0000658

Steroid esters

0.91 (0.83–0.99)

0.030

0.92 (0.84–1.01)

0.082

0.88 (0.79–0.97)

0.011

C34:1 PC

HMDB0007972

Glycerophosphocholines

0.91 (0.83–1.00)

0.040

0.93 (0.85–1.02)

0.138

0.87 (0.78–0.98)

0.016

C34:3 PC

HMDB0008006

Glycerophosphocholines

0.91 (0.83–1.00)

0.039

0.92 (0.84–1.01)

0.099

0.88 (0.79–0.98)

0.022

C32:1 PC

HMDB0007873

Glycerophosphocholines

0.91 (0.83–0.99)

0.039

0.94 (0.85–1.03)

0.199

0.88 (0.79–0.98)

0.023

Indoxyl sulfate

HMDB0000682

Arylsulfates

0.88 (0.81–0.96)

0.005

0.87 (0.80–0.96)

0.003

0.90 (0.82–1.00)

0.042

  1. CE cholesteryl ester, PC phosphatidylcholine, PS phosphatidylserine, TAG triacylglycerides, OR odds ratio, CI confidence interval.
  2. Model 1: Unadjusted conditional logistic regression model.
  3. Model 2: Model 1+ BMI at age 18, weight change (from age 18 to time of first blood draw).
  4. Model 3: Model 2+ age at menarche, parity and age at first birth, breastfeeding history, family history of breast cancer in a first degree relative, personal history of benign breast disease, physical activity, alcohol intake (by quintile), and oral contraceptive use at blood collection.
Back to article page